Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 3/2008

01-05-2008 | Research Paper

The laminin α-1 chain derived peptide, AG73, increases fibronectin levels in breast and melanoma cancer cells

Authors: Jean A. Engbring, Rydhwana Hossain, Sherilyn J. VanOsdol, Benjamin Kaplan-Singer, Michael Wu, Suguru Hibino, Jennifer E. Koblinski

Published in: Clinical & Experimental Metastasis | Issue 3/2008

Login to get access

Abstract

Laminin-111 promotes the malignant phenotype, and a 12-mer synthetic peptide (AG73, RKRLQVQLSIRT) from the carboxyl terminus of the α1 chain increases B16F10 melanoma metastasis to the lung and liver. Using an antibody array, fibronectin was identified as an up-regulated protein in B16F10 cells after incubation with this peptide. The increased fibronectin is cell-associated with no increase in soluble fibronectin. The AG73 peptide increased the number and size of bone metastases with both B16F10 melanoma and MDA-231 breast carcinoma cells in an intracardiac injection model. Using siRNA transfection, we found that a reduction in fibronectin expression did not reduce bone metastasis in the presence of the metastasis-promoting peptide AG73. We conclude that the laminin peptide AG73 increases metastasis independently of fibronectin expression.
Literature
1.
Colognato H, Yurchenco PD (2000) Form and function: the laminin family of heterotrimers. Dev Dyn 218:213–234PubMedCrossRef
2.
Aumailley M, Bruckner-Tuderman L, Carter WG et al (2005) A simplified laminin nomenclature. Matrix Biol 24:326–332PubMedCrossRef
3.
Kleinman HK, Koblinski J, Lee S et al (2001) Role of basement membrane in tumor growth and metastasis. Surg Oncol Clin N Am 10:329–338, ix
4.
Givant-Horwitz V, Davidson B, Reich R (2005) Laminin-induced signaling in tumor cells. Cancer Lett 223:1–10PubMedCrossRef
5.
Kanemoto T, Reich R, Royce L et al (1990) Identification of an amino acid sequence from the laminin A chain that stimulates metastasis and collagenase IV production. Proc Natl Acad Sci USA 87:2279–2283PubMedCrossRef
6.
Stack MS, Gray RD, Pizzo SV (1993) Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain. Cancer Res 53:1998–2004PubMed
7.
Stack MS, Pizzo SV (1994) The effect of substituted laminin A chain-derived peptides on the conformation and activation kinetics of plasminogen. Arch Biochem Biophys 309:117–122PubMedCrossRef
8.
Yamamura K, Kibbey MC, Kleinman HK (1993) Melanoma cells selected for adhesion to laminin peptides have different malignant properties. Cancer Res 53:423–428PubMed
9.
Ponce ML, Nomizu M, Kleinman HK (2001) An angiogenic laminin site and its antagonist bind through the alpha(v)beta3 and alpha5beta1 integrins. Faseb J 15:1389–1397PubMedCrossRef
10.
Kuratomi Y, Nomizu M, Tanaka K et al (2002) Laminin gamma 1 chain peptide, C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16-F10 mouse melanoma cells. Br J Cancer 86:1169–1173PubMedCrossRef
11.
Ponce ML, Kleinman HK (2003) Identification of redundant angiogenic sites in laminin alpha1 and gamma1 chains. Exp Cell Res 285:189–195PubMedCrossRef
12.
Graf J, Iwamoto Y, Sasaki M et al (1987) Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 48:989–996PubMedCrossRef
13.
Iwamoto Y, Robey FA, Graf J et al (1987) YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238:1132–1134PubMedCrossRef
14.
Nakai M, Mundy GR, Williams PJ et al (1992) A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 52:5395–5399PubMed
15.
Sakamoto N, Iwahana M, Tanaka NG et al (1991) Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res 51:903–906PubMed
16.
Kim WH, Nomizu M, Song SY et al (1998) Laminin-alpha1-chain sequence Leu-Gln-Val-Gln-Leu-Ser-Ile-Arg (LQVQLSIR) enhances murine melanoma cell metastases. Int J Cancer 77:632–639PubMedCrossRef
17.
Yoshida Y, Hosokawa K, Dantes A et al (2001) Role of laminin in ovarian cancer tumor growth and metastasis via regulation of Mdm2 and Bcl-2 expression. Int J Oncol 18:913–921PubMed
18.
Song SY, Nomizu M, Yamada Y et al (1997) Liver metastasis formation by laminin-1 peptide (LQVQLSIR)-adhesion selected B16-F10 melanoma cells. Int J Cancer 71:436–441PubMedCrossRef
19.
Engbring JA, Hoffman MP, Karmand AJ et al (2002) The B16F10 cell receptor for a metastasis-promoting site on laminin-1 is a heparan sulfate/chondroitin sulfate-containing proteoglycan. Cancer Res 62:3549–3554PubMed
20.
Hoffman MP, Engbring JA, Nielsen PK et al (2001) Cell type-specific differences in glycosaminoglycans modulate the biological activity of a heparin-binding peptide (RKRLQVQLSIRT) from the G domain of the laminin alpha1 chain. J Biol Chem 276:22077–22085PubMedCrossRef
21.
Suzuki N, Ichikawa N, Kasai S et al (2003) Syndecan binding sites in the laminin alpha1 chain G domain. Biochemistry 42:12625–12633PubMedCrossRef
22.
Hozumi K, Suzuki N, Nielsen PK et al (2006) Laminin alpha1 chain LG4 module promotes cell attachment through syndecans and cell spreading through integrin alpha2beta1. J Biol Chem 281:32929–32940PubMedCrossRef
23.
Mochizuki M, Philp D, Hozumi K et al (2007) Angiogenic activity of syndecan-binding laminin peptide AG73 (RKRLQVQLSIRT). Arch Biochem Biophys 459:249–255PubMedCrossRef
24.
Maniotis AJ, Folberg R, Hess A et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:739–752PubMed
25.
Clark EA, Golub TR, Lander ES et al (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535PubMedCrossRef
26.
Zhang L, Zhou W, Velculescu VE et al (1997) Gene expression profiles in normal and cancer cells. Science 276:1268–1272PubMedCrossRef
27.
Larsen M, Tremblay ML, Yamada KM (2003) Phosphatases in cell-matrix adhesion and migration. Nat Rev Mol Cell Biol 4:700–711PubMedCrossRef
28.
Arguello F, Baggs RB, Frantz CN (1988) A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48:6876–6881PubMed
29.
Wierzbicka-Patynowski I, Schwarzbauer JE (2003) The ins and outs of fibronectin matrix assembly. J Cell Sci 116:3269–3276PubMedCrossRef
30.
Pankov R, Cukierman E, Katz BZ et al (2000) Integrin dynamics and matrix assembly: tensin-dependent translocation of alpha(5)beta(1) integrins promotes early fibronectin fibrillogenesis. J Cell Biol 148:1075–1090PubMedCrossRef
31.
Pollard TD, Borisy GG (2003) Cellular motility driven by assembly and disassembly of actin filaments. Cell 112:453–465PubMedCrossRef
32.
Dunsmore SE, Martinez-Williams C, Goodman RA et al (1995) Turnover of fibronectin and laminin by alveolar epithelial cells. Am J Physiol 269:L766–775PubMed
33.
Polin RA, Yoder MC, Douglas SD et al (1989) Fibronectin turnover in the premature neonate measured with [15N]glycine. Am J Clin Nutr 49:314–319PubMed
34.
Huijzer JC, Uhlenkott CE, Meadows GG (1995) Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion. Int J Cancer 63:92–99PubMedCrossRef
35.
Fidler IJ (1973) Selection of successive tumour lines for metastasis. Nat New Biol 242:148–149PubMed
36.
Yoneda T, Sasaki A, Mundy GR (1994) Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32:73–84PubMedCrossRef
Metadata
Title
The laminin α-1 chain derived peptide, AG73, increases fibronectin levels in breast and melanoma cancer cells
Authors
Jean A. Engbring
Rydhwana Hossain
Sherilyn J. VanOsdol
Benjamin Kaplan-Singer
Michael Wu
Suguru Hibino
Jennifer E. Koblinski
Publication date
01-05-2008
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 3/2008
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-007-9138-y

Other articles of this Issue 3/2008

Clinical & Experimental Metastasis 3/2008 Go to the issue

Research Paper

Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen

Research Paper

Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin

Research Paper

Graded hypoxia modulates the invasive potential of HT1080 fibrosarcoma and MDA MB231 carcinoma cells

Research Paper

Intracellular esterase activity in living cells may distinguish between metastatic and tumor-free lymph nodes

Research paper

Impact of sentinel lymphadenectomy on survival in a murine model of melanoma

Research Paper

Alterations in Cx43 and OB-cadherin affect breast cancer cell metastatic potential
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits